Statens Serum Institut

ssi.dk

Statens Serum Institut (SSI) is a member of the Ministry of Health and Senior Affairs. Our main task is to ensure preparedness for infectious diseases, congenital disorders and biological threats. We monitor a large number of infectious diseases in Denmark and keep an eye on developments around the world via our international collaborations. Against this background, we advise healthcare professionals on prevention and treatment and advise decision-makers in situations that require special measures, for example in case of epidemics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

GINKGO BIOWORKS AND THE GOVERNMENT OF THE REPUBLIC OF PANAMA ANNOUNCE PLANS TO ESTABLISH NEW BIOSECURITY CAPABILITIES

PRNewswire | August 07, 2023

news image

Ginkgo Bioworks the leading horizontal platform for cell programming and biosecurity, and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Latin America. Ginkgo, through its biosecurity and public health unit, Concentric by Ginkgo, aims to support the Gorgas Institute as it...

Read More

Industrial Impact

NEW DATA REVEAL MOLECULAR DRIVERS OF THYROID EYE DISEASE (TED) MAY REMAIN ACTIVATED IN PATIENTS WITH LOW CLINICAL ACTIVITY SCORE (CAS)

Horizon | October 03, 2022

news image

Horizon Therapeutics plc announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting Sept. 30 – Oct. 3 in Chicago. TED is a progressive and potentially vision-threatening rare autoimmune disease, which has been historically characterized as biphasic: acute, which is traditionally believe...

Read More

Cell and Gene Therapy

MATICA BIO ANNOUNCES JOINT RESEARCH AGREEMENT WITH SARTORIUS FOR THE DEVELOPMENT OF ADVANCED VIRAL VECTOR MANUFACTURING TECHNOLOGY

Matica Biotechnology, Inc. | October 19, 2021

news image

Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies together to streamline and optimize PAT technologies, automation software, and single-use platforms offe...

Read More

TYLIGAND BIOSCIENCE AND CONTEXT THERAPEUTICS SIGN STRATEGIC DEVELOPMENT AGREEMENT FOR ONAPRISTONE ER

BioSpace | March 12, 2020

news image

Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...

Read More
news image

Medical, Industry Outlook

GINKGO BIOWORKS AND THE GOVERNMENT OF THE REPUBLIC OF PANAMA ANNOUNCE PLANS TO ESTABLISH NEW BIOSECURITY CAPABILITIES

PRNewswire | August 07, 2023

Ginkgo Bioworks the leading horizontal platform for cell programming and biosecurity, and the Government of the Republic of Panama's Gorgas Memorial Institute for Health Studies, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent to develop and implement new biosecurity capabilities in Latin America. Ginkgo, through its biosecurity and public health unit, Concentric by Ginkgo, aims to support the Gorgas Institute as it...

Read More
news image

Industrial Impact

NEW DATA REVEAL MOLECULAR DRIVERS OF THYROID EYE DISEASE (TED) MAY REMAIN ACTIVATED IN PATIENTS WITH LOW CLINICAL ACTIVITY SCORE (CAS)

Horizon | October 03, 2022

Horizon Therapeutics plc announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting Sept. 30 – Oct. 3 in Chicago. TED is a progressive and potentially vision-threatening rare autoimmune disease, which has been historically characterized as biphasic: acute, which is traditionally believe...

Read More
news image

Cell and Gene Therapy

MATICA BIO ANNOUNCES JOINT RESEARCH AGREEMENT WITH SARTORIUS FOR THE DEVELOPMENT OF ADVANCED VIRAL VECTOR MANUFACTURING TECHNOLOGY

Matica Biotechnology, Inc. | October 19, 2021

Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies together to streamline and optimize PAT technologies, automation software, and single-use platforms offe...

Read More
news image

TYLIGAND BIOSCIENCE AND CONTEXT THERAPEUTICS SIGN STRATEGIC DEVELOPMENT AGREEMENT FOR ONAPRISTONE ER

BioSpace | March 12, 2020

Tyligand Bioscience, Ltd., a leader in small molecule drug discovery and development, and Context Therapeutics LLC, a clinical stage biopharmaceutical company focused on hormone driven cancers, today announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). Onapristone ER is currently being evaluated in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers in t...

Read More